The Effect of Proton Pump Inhibitors on Barrett's Esophagus

Kerry B. Dunbar; Rhonda F. Souza; Stuart J. Spechler

doi:10.1016/j.gtc.2015.02.010

The Effect of Proton Pump Inhibitors on Barrett's Esophagus

Kerry B. Dunbar, Rhonda F. Souza, Stuart J. Spechler

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Proton pump inhibitors (PPIs) may protect against carcinogenesis in Barrett's esophagus because they eliminate the chronic esophageal inflammation of reflux esophagitis, and because they decrease esophageal exposure to acid, which can cause cancer-promoting DNA damage and increase proliferation in Barrett's metaplasia. Most clinical studies of PPIs and cancer development in Barrett's esophagus have found a cancer-protective effect for these drugs, although there are some contradictory data. Chemoprevention of dysplasia and cancer in Barrett's esophagus with PPIs appears to be cost-effective, and the indirect evidence supporting a cancer-protective role for PPIs is strong enough to warrant PPI treatment of virtually all patients with Barrett's esophagus.

Original language	English (US)
Pages (from-to)	415-424
Number of pages	10
Journal	Gastroenterology Clinics of North America
Volume	44
Issue number	2
DOIs	https://doi.org/10.1016/j.gtc.2015.02.010
State	Published - Jun 1 2015
Externally published	Yes

Keywords

Barrett's esophagus
Dysplasia
Esophageal cancer
Gastroesophageal reflux disease
Proton pump inhibitor

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1016/j.gtc.2015.02.010

Cite this

@article{dac34d0181f8443e9c0eeeb62857ab8f,

title = "The Effect of Proton Pump Inhibitors on Barrett's Esophagus",

abstract = "Proton pump inhibitors (PPIs) may protect against carcinogenesis in Barrett's esophagus because they eliminate the chronic esophageal inflammation of reflux esophagitis, and because they decrease esophageal exposure to acid, which can cause cancer-promoting DNA damage and increase proliferation in Barrett's metaplasia. Most clinical studies of PPIs and cancer development in Barrett's esophagus have found a cancer-protective effect for these drugs, although there are some contradictory data. Chemoprevention of dysplasia and cancer in Barrett's esophagus with PPIs appears to be cost-effective, and the indirect evidence supporting a cancer-protective role for PPIs is strong enough to warrant PPI treatment of virtually all patients with Barrett's esophagus.",

keywords = "Barrett's esophagus, Dysplasia, Esophageal cancer, Gastroesophageal reflux disease, Proton pump inhibitor",

author = "Dunbar, {Kerry B.} and Souza, {Rhonda F.} and Spechler, {Stuart J.}",

year = "2015",

month = jun,

day = "1",

doi = "10.1016/j.gtc.2015.02.010",

language = "English (US)",

volume = "44",

pages = "415--424",

journal = "Gastroenterology Clinics of North America",

issn = "0889-8553",

publisher = "W.B. Saunders",

number = "2",

}

TY - JOUR

T1 - The Effect of Proton Pump Inhibitors on Barrett's Esophagus

AU - Dunbar, Kerry B.

AU - Souza, Rhonda F.

AU - Spechler, Stuart J.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Proton pump inhibitors (PPIs) may protect against carcinogenesis in Barrett's esophagus because they eliminate the chronic esophageal inflammation of reflux esophagitis, and because they decrease esophageal exposure to acid, which can cause cancer-promoting DNA damage and increase proliferation in Barrett's metaplasia. Most clinical studies of PPIs and cancer development in Barrett's esophagus have found a cancer-protective effect for these drugs, although there are some contradictory data. Chemoprevention of dysplasia and cancer in Barrett's esophagus with PPIs appears to be cost-effective, and the indirect evidence supporting a cancer-protective role for PPIs is strong enough to warrant PPI treatment of virtually all patients with Barrett's esophagus.

AB - Proton pump inhibitors (PPIs) may protect against carcinogenesis in Barrett's esophagus because they eliminate the chronic esophageal inflammation of reflux esophagitis, and because they decrease esophageal exposure to acid, which can cause cancer-promoting DNA damage and increase proliferation in Barrett's metaplasia. Most clinical studies of PPIs and cancer development in Barrett's esophagus have found a cancer-protective effect for these drugs, although there are some contradictory data. Chemoprevention of dysplasia and cancer in Barrett's esophagus with PPIs appears to be cost-effective, and the indirect evidence supporting a cancer-protective role for PPIs is strong enough to warrant PPI treatment of virtually all patients with Barrett's esophagus.

KW - Barrett's esophagus

KW - Dysplasia

KW - Esophageal cancer

KW - Gastroesophageal reflux disease

KW - Proton pump inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84929948120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929948120&partnerID=8YFLogxK

U2 - 10.1016/j.gtc.2015.02.010

DO - 10.1016/j.gtc.2015.02.010

M3 - Article

C2 - 26021202

AN - SCOPUS:84929948120

SN - 0889-8553

VL - 44

SP - 415

EP - 424

JO - Gastroenterology Clinics of North America

JF - Gastroenterology Clinics of North America

IS - 2

ER -

The Effect of Proton Pump Inhibitors on Barrett's Esophagus

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this